Yosemite
VC Fund
San Francisco, United States
Yosemite is a VC fund in San Francisco focused on Health Care and Biotechnology. Yosemite supports the development of technologies and treatments intended to reduce cancer mortality. The company collaborates with researchers, scientists, and entrepreneurs working across the oncology sector, aiming to accelerate progress in diagnostics, therapies, and care delivery. Yosemite funds projects ranging from early-stage nonprofit initiatives to later-stage companies, providing capital across the full spectrum of cancer innovation. Its investment approach is structured to catalyze breakthroughs that contribute to making cancer a manageable and non-lethal condition. Yosemite's portfolio spans various domains of cancer research and treatment, including targeted therapies, immuno-oncology, early detection, and patient-centric solutions.
- Total investments:
- 20
- Last investment:
- Lead investor:
- 40%
- Fund size:
- $200M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Yosemite invests in
Stages Yosemite invests in
Countries Yosemite invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $4.3M–$86M
- Series A
- $20M–$120M
- Series B
- $30M–$175M
Investment Focus
Industry
- Health Care 9 (45%)
- Biotechnology 8 (40%)
- Medical 6 (30%)
- Artificial Intelligence 4 (20%)
- Life Science 3 (15%)
Stage
- Seed 6 (30%)
- Series A 6 (30%)
- Series B 3 (15%)
- Series C 2 (10%)
- Funding Round 2 (10%)
Country
- United States 13 (65%)
- Australia 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Reed Jobs
Founder
|
Founder | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Skopos Bio is an Australian biotechnology company developing targeted radiopharmaceutical therapies for cancer treatment. | $8.3M / Seed / Sep 30, 2026 | ||
| Chai Discovery creates Chai-1, a multi-modal foundation model designed for predicting molecular structures relevant to drug discovery. The model facilitates the unified prediction of proteins, small molecules, and nucleic acids, and is available for free for commercial applications. By enabling accurate predictions without the need for multiplesequence alignments, Chai-1 advances the capabilities of molecular modeling in the life sciences. | $400M / Series C / Jul 14, 2026 | ||
| HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels. | Jun 22, 2026 | ||
| Turquoise Health is a health tech company that simplifies administration to reduce the expense and complexity of healthcare. The company was founded in 2020 and is a fully remote company headquartered in San Diego, California, United States. | $40M / Series C / Mar 17, 2026 | ||
| Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI andstate-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable. | Venture - Series Unknown / Feb 19, 2026 | ||
| Proxima Bio develops programmable medicines that modulate protein interactions to address disease processes. It focuses on creating proximity-modulating therapeutics that direct protein interactions for potential use in conditions such as autoimmune disorders and cancer, expanding the range of targets that traditional drugs cannot easily reach.Proxima Bio combines structural biology, data generation, and machine learning to identify actionable protein-protein interfaces and support the discovery of new therapeutic modalities. The company works with pharmaceutical partners to apply its platform in research collaborations and advance drug discovery pipelines. Proxima Bio’s platform integrates multiple technologies to support the design and discovery of novel proximity-based treatment approaches. | $86.3M / Seed / Jan 13, 2026 | ||
| Chai Discovery creates Chai-1, a multi-modal foundation model designed for predicting molecular structures relevant to drug discovery. The model facilitates the unified prediction of proteins, small molecules, and nucleic acids, and is available for free for commercial applications. By enabling accurate predictions without the need for multiplesequence alignments, Chai-1 advances the capabilities of molecular modeling in the life sciences. | $130M / Series B / Dec 15, 2025 | ||
Quarry Thera
|
Quarry Thera is a biotech company distinguished by its innovative therapeutic pipeline and an unprecedented platform that enables the development of cutting-edge treatments with the potential to address significant unmet medical needs. | $32M / Series A / Nov 26, 2025 | |
| Solve Therapeutics is a biopharmaceutical company that develops Antibody Drug Conjugate and Bispecific Therapeutics. The company was founded in 2021 and is headquartered in Belmont, California. | $120M / Series A / Nov 17, 2025 | ||
| Azalea Therapeutics is a biotechnology company pioneering precision genome engineering directly inside the body, with a primary focus on developing cancer immunotherapies. Their innovative approach uses Envelope Delivery Vehicles (EDVs) to selectively locate and deliver genome editing tools to T cells within the patient, enabling the engineering ofthese cells in vivo rather than ex vivo (outside the body). This method aims to transform the patient’s own T cells into powerful cancer therapies safely and efficiently. | $65M / Series A / Nov 04, 2025 | ||
| See all 20 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Yosemite invest in?
Yosemite invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series A stage. Most of the 20 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Yosemite invest in?
Yosemite typically joins rounds of $4.3M–$86M at Seed, $20M–$120M at Series A and $30M–$175M at Series B. These are whole funding-round sizes, not Yosemite's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Yosemite took part in.
How do I contact Yosemite?
Public channels for Yosemite include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Yosemite?
The team at Yosemite includes Reed Jobs (Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
